Novo Nordisk's GLP-1 surge tightens peptide capacity outlook

Novo Nordisk's Q1 2026 results confirm what supply-chain directors and plant heads have been tracking: GLP-1 volume growth is outpacing price erosion, and the oral semaglutide ramp is accelerating faster than any prior GLP-1 launch in the US market.

Oral Wegovy tops 2 million prescriptions in its first quarter

Launched in the US on 5 January 2026, the Wegovy pill recorded more than 2 million total prescriptions by mid-April, with weekly prescriptions exceeding 200,000 for the week ending 17 April. Q1 2026 net sales for the oral formulation reached DKK 2,256 million, partially shaped by pre-launch pipeline fill with wholesalers and telehealth partners. Novo Nordisk describes it as the strongest-ever GLP-1 volume launch in the US.

Adjusted obesity care sales grew 22% at constant exchange rates (CER) in Q1 2026, even as US Operations adjusted sales declined 11% at CER, driven by lower realised prices. International Operations sales rose 6% at CER on higher volumes. Adjusted operating profit reached DKK 32,858 million, down 6% at CER when the USD 4.2 billion non-recurring 340B Drug Pricing Program provision reversal is excluded. The company has raised its full-year 2026 guidance for both adjusted sales and adjusted operating profit, now projecting growth of -4% to -12% at CER on an adjusted basis.

On the injectable side, Wegovy HD (semaglutide 7.2 mg) received FDA approval in March and launched on 7 April, with the STEP UP trial reporting 20.7% mean weight loss. The FDA also approved Awiqli, a once-weekly basal insulin for type 2 diabetes, during the quarter.

Where oral solid dose and peptide fill-finish teams feel the pressure

The oral Wegovy trajectory creates a dual manufacturing challenge: sustaining injectable semaglutide supply for the established Wegovy subcutaneous portfolio while scaling oral solid dose capacity for a formulation that is still in its launch ramp. For plant heads managing peptide active pharmaceutical ingredient (API) synthesis and fill-finish lines, the 200,000-prescription weekly run rate is a planning signal, not a ceiling.

International launches of the Wegovy pill are pending regulatory decisions and are expected in the second half of 2026, which compresses the timeline for ex-US manufacturing readiness. Supply-chain leads should be mapping wholesaler and distribution network requirements now, given the pre-launch pipeline fill dynamics that shaped Q1 US sales figures. The zenagamtide AMAZE phase 3 programme, initiated during the quarter, adds a further peptide candidate to the long-range capacity planning horizon.

The ex-US launch window and the regulatory calendar to track

The most actionable forward signal in the Q1 report is the H2 2026 target for first Wegovy pill launches outside the US, contingent on pending regulatory decisions in each market. For regulatory affairs leads at contract manufacturers and at sites supporting Novo Nordisk's supply network, the relevant checkpoint is the sequence and timing of those ex-US approvals, which will determine when manufacturing commitments must be confirmed.

The etavopivat HIBISCUS phase 3 trial also met both co-primary endpoints in sickle cell disease, adding a non-GLP-1 pipeline asset that will eventually require its own process validation and commercial-scale manufacturing plan.

The H2 2026 ex-US Wegovy pill regulatory decisions will set the next hard deadline for manufacturing readiness across Novo Nordisk's international supply network.